Pubblicazioni

A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group  (2024)

Autori:
Barilà, Gregorio; Quaglia, Francesca Maria; Furlan, Anna; Pescosta, Norbert; Bonalumi, Angela; Marcon, Chiara; Pascarella, Anna; Tinelli, Martina; De March, Elena; Lico, Albana; Sartori, Roberto; Clissa, Cristina; De Sabbata, Giovanni; Nappi, Davide; Porrazzo, Marika; De Marchi, Roberta; Pavan, Laura; Tosetto, Alberto; Gherlinzoni, Filippo; Krampera, Mauro; Bassan, Renato; Patriarca, Francesca; Semenzato, Gianpietro; Zambello, Renato
Titolo:
A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group
Anno:
2024
Tipologia prodotto:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Lingua:
Inglese
Referee:
No
Nome rivista:
Annals of Hematology
ISSN Rivista:
0939-5555
N° Volume:
103
Numero o Fascicolo:
1
Intervallo pagine:
125-132
Parole chiave:
D-VD; Lenalidomide refractoriness; Multiple myeloma; Real-life
Breve descrizione dei contenuti:
Treatment of lenalidomide refractory (Len-R) multiple myeloma (MM) patients still represents an unmet clinical need. In the last years, daratumumab-bortezomib-dexamethasone (D-VD) combination was extensively used in this setting, even though only a small fraction of Len-R patients was included in the pivotal trial. This real-life study aimed to evaluate the efficacy and safety of the D-VD regimen in a cohort that exclusively enrolled Len exposed or refractory MM patients. The study cohort included 57 patients affected by relapsed/refractory MM. All patients were previously exposed to Len, with 77.2% being refractory. The overall response rate (ORR) was 79.6% with 43% of cases obtaining at least a very good partial response (VGPR). The D-VD regimen showed a favorable safety profile, with low frequency of grade 3-4 adverse events, except for thrombocytopenia observed in 21.4% of patients. With a median follow-up of 13 months, median progression-free survival (PFS) was 17 months. No significant PFS differences were observed according to age, ISS, LDH levels, type of relapse, and high-risk FISH. Len exposed patients displayed a PFS advantage as compared to Len refractory patients (29 vs 16 months, p = 0.2876). Similarly, patients treated after Len maintenance showed a better outcome as compared to patients who had received a full-dose Len treatment (23 vs 13 months, p = 0.1728). In conclusion, our real-world data on D-VD combination showed remarkable efficacy in Len-R patients, placing this regimen as one of the standards of care to be properly taken into account in this MM setting.
Id prodotto:
139549
Handle IRIS:
11562/1126171
ultima modifica:
27 settembre 2024
Citazione bibliografica:
Barilà, Gregorio; Quaglia, Francesca Maria; Furlan, Anna; Pescosta, Norbert; Bonalumi, Angela; Marcon, Chiara; Pascarella, Anna; Tinelli, Martina; De March, Elena; Lico, Albana; Sartori, Roberto; Clissa, Cristina; De Sabbata, Giovanni; Nappi, Davide; Porrazzo, Marika; De Marchi, Roberta; Pavan, Laura; Tosetto, Alberto; Gherlinzoni, Filippo; Krampera, Mauro; Bassan, Renato; Patriarca, Francesca; Semenzato, Gianpietro; Zambello, Renato, A real-life study of daratumumab-bortezomib-dexamethasone (D-VD) in lenalidomide exposed/refractory multiple myeloma patients: a report from the Triveneto Myeloma Working Group «Annals of Hematology » , vol. 103 , n. 12024pp. 125-132

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo IRIS

<<indietro
Condividi